Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

FDA-Approved Oligonucleotide Therapies in 2017

31 Mar 2017

Abstract excerpt

Oligonucleotides (oligos) have been under clinical development for approximately the past 30 years, beginning with antisense oligonucleotides (ASOs) and apatmers and followed about 15 years ago by siRNAs. During that lengthy period of time, numerous clinical trials have been performed and thousands of trial participants accrued onto studies. Of all the molecules evaluated as of January 2017, the regulatory...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytomegalovirus and herpesvirus research
Share to DNA and Nucleic Acid Chemistry
Share to RNA Interference and Gene Delivery

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28366767
DOI: 10.1016/j.ymthe.2017.03.023

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

FDA-Approved Oligonucleotide Therapies in 2017PMID 28366767Read ↗

Antisense Oligonucleotides: Technological Advances, Clinical Progress, and Expanding Therapeutic FrontiersSemantic proximity Read ↗

Clinical Applications of Single-Stranded Oligonucleotides: Current Landscape of Approved and In-Development TherapeuticsSemantic proximity Read ↗

The Versatile Applications of Antisense Oligonucleotides in Modern MedicineSemantic proximity Read ↗

Antisense oligonucleotide: A promising therapeutic option to beat COVID ‐19Semantic proximity Read ↗

Small Drugs, Huge Impact: The Extraordinary Impact of Antisense Oligonucleotides in Research and Drug DevelopmentSemantic proximity Read ↗

Antisense oligonucleotides: A promising advancement in neurodegenerative disease treatmentSemantic proximity Read ↗

Telomerase inhibition, oligonucleotides, and clinical trialsSemantic proximity Read ↗

Antisense technology: A reviewSemantic proximity Read ↗

Antisense Oligonucleotide-Based Therapy of Viral InfectionsSemantic proximity Read ↗

Research and Development of Oligonucleotide Therapeutics in Japan for Rare DiseasesSemantic proximity Read ↗

Oligonucleotide-based therapy for neurodegenerative diseasesSemantic proximity Read ↗

Targeting RNA : A Transformative Therapeutic StrategySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.